New York, United States
Gameto, founded in 2020, is a pioneering biotechnology firm headquartered in the United States, aiming to transform female reproductive health through innovative cell therapies. Their mission is encapsulated in their compelling slogan: "Redefining female reproductive health by developing cell therapies that improve lives."
Operating within the Biopharma, Biotechnology, and Life Sciences sectors, Gameto addresses a critical gap in women's health, an area often underserved with limited and complex treatment options. By utilizing advanced cellular engineering, the company has developed a proprietary platform that reprograms hiPSCs into engineered ovarian and endometrium cell lines. The versatility of this platform has led to a pipeline of cellular therapeutics.
Gameto's flagship product, Fertilo, seeks to enhance IVF and egg freezing procedures, while future initiatives like Deovo and Ameno aim to further exploit this platform. The company secured a $33.00M Series B investment on May 29, 2024, backed by prominent investors including TA Ventures, Two Sigma Ventures, Insight Partners, and others, validating their innovative approach to women's health.
